依托泊苷和顺铂用于晚期肾上腺皮质癌的细胞毒性治疗
Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma.
作者信息
Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M, Cailleux A F, Nakib I, Schlumberger M
机构信息
Institut Gustave Roussy, Villejuif, France.
出版信息
Br J Cancer. 1998 Aug;78(4):546-9. doi: 10.1038/bjc.1998.530.
Abstract
Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m(-2) day(-1) on days 1-3) and cisplatin (100 mg m(-2) day(-1) on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels >14 mg l(-1). Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.
摘要
肾上腺皮质癌（ACC）是一种预后较差的罕见肿瘤。顺铂是在该疾病中测试最广泛的细胞毒性药物。总共招募了18例晚期ACC患者。细胞毒性治疗方案为依托泊苷（VP16）（第1 - 3天，100 mg m⁻² 每日）和顺铂（第1天，100 mg m⁻²），每4周重复一次。14例患者在化疗期间持续使用米托坦治疗。3例患者完全缓解，3例部分缓解，总缓解率为33%。在6例米托坦有效剂量治疗期间病情进展的患者中，有3例观察到肿瘤反应，血清水平>14 mg l⁻¹表明了这一点。毒性作用如预期，无生命危险；无需中断治疗。
相似文献
1
Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma.依托泊苷和顺铂用于晚期肾上腺皮质癌的细胞毒性治疗
Br J Cancer. 1998 Aug;78(4):546-9. doi: 10.1038/bjc.1998.530.
2
3
4
Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.米托坦与顺铂、依托泊苷和阿霉素联合用于晚期儿童肾上腺皮质癌：米托坦监测与肿瘤消退
J Pediatr Hematol Oncol. 2006 Aug;28(8):513-24. doi: 10.1097/01.mph.0000212965.52759.1c.
5
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.依托泊苷、阿霉素和顺铂联合米托坦治疗晚期肾上腺皮质癌：一项大型前瞻性II期试验。
Endocr Relat Cancer. 2005 Sep;12(3):657-66. doi: 10.1677/erc.1.01025.
6
Cytotoxic chemotherapy for adrenocortical carcinoma.肾上腺皮质癌的细胞毒性化疗。
Minerva Endocrinol. 1995 Mar;20(1):105-9.
7
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.转移性肾上腺皮质癌联合化疗与手术切除的II期试验：持续输注阿霉素、长春新碱和依托泊苷，每日服用米托坦作为P-糖蛋白拮抗剂。
Cancer. 2002 May 1;94(9):2333-43. doi: 10.1002/cncr.10487.
8
Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases.转移性肾上腺皮质癌对依托泊苷、阿霉素和顺铂（EAP）化疗的良好反应。两例报告。
Tumori. 1992 Oct 31;78(5):345-8. doi: 10.1177/030089169207800512.
9
Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p'DDD. Clinical case reports.在o,p'DDD治疗失败后，用依托泊苷（VP - 16）和顺铂治疗转移性肾上腺皮质癌。临床病例报告。
Am J Clin Oncol. 1996 Jun;19(3):229-31. doi: 10.1097/00000421-199606000-00003.
10
Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.一种针对肾上腺皮质癌的脂质体化疗方案的临床前进展及首次转化步骤
Endocr Relat Cancer. 2016 Oct;23(10):825-37. doi: 10.1530/ERC-16-0249. Epub 2016 Aug 22.
引用本文的文献
1
Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches.不可切除或转移性肾上腺皮质癌的系统治疗前沿：利用新型治疗方法
Clin Med Insights Oncol. 2025 Aug 29;19:11795549251364042. doi: 10.1177/11795549251364042. eCollection 2025.
2
Identification of Molecular Subtypes and Prognostic Characteristics of Adrenocortical Carcinoma Based on Unsupervised Clustering.基于无监督聚类的肾上腺皮质癌分子亚型鉴定和预后特征。
Int J Mol Sci. 2023 Oct 23;24(20):15465. doi: 10.3390/ijms242015465.
3
Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma.病例报告：新型联合用药米托坦、依托泊苷、顺铂和替雷利珠单抗治疗转移性肾上腺皮质癌患者取得显著疗效。
Front Endocrinol (Lausanne). 2023 Sep 8;14:1115893. doi: 10.3389/fendo.2023.1115893. eCollection 2023.
4
Re-Evaluation of Combinational Efficacy and Synergy of the Italian Protocol In Vitro: Are We Truly Optimizing Benefit or Permitting Unwanted Toxicity?意大利方案体外联合疗效与协同作用的再评估：我们真的在优化益处还是在允许不必要的毒性？
Biomedicines. 2021 Sep 10;9(9):1190. doi: 10.3390/biomedicines9091190.
5
The challenge of developmental therapeutics for adrenocortical carcinoma.肾上腺皮质癌的发育治疗学挑战。
Oncotarget. 2016 Jul 19;7(29):46734-46749. doi: 10.18632/oncotarget.8774.
6
Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy.难治性肾上腺皮质癌的分子特征分析及治疗预测生物标志物
Biomark Cancer. 2015 Dec 17;7:69-76. doi: 10.4137/BIC.S34292. eCollection 2015.
7
Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).肾上腺皮质癌的管理：意大利内分泌学会（SIE）的共识声明
J Endocrinol Invest. 2016 Jan;39(1):103-21. doi: 10.1007/s40618-015-0349-9. Epub 2015 Jul 14.
8
Management of adrenal cancer: a 2013 update.肾上腺癌的治疗：2013 年更新版
J Endocrinol Invest. 2014 Mar;37(3):207-17. doi: 10.1007/s40618-013-0049-2.
9
Adrenocortical carcinoma.肾上腺皮质癌。
Endocr Rev. 2014 Apr;35(2):282-326. doi: 10.1210/er.2013-1029. Epub 2013 Dec 20.
10
Mixed corticomedullary adrenal carcinoma.混合型皮质-髓质肾上腺皮质癌。
Surg Today. 2013 Nov;43(11):1232-9. doi: 10.1007/s00595-012-0458-4. Epub 2013 Feb 23.
本文引用的文献
1
Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study.米托坦和顺铂治疗肾上腺皮质癌患者的II期试验：一项西南肿瘤协作组的研究。
J Clin Oncol. 1993 Jan;11(1):161-5. doi: 10.1200/JCO.1993.11.1.161.
2
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.米托坦治疗肾上腺皮质癌的最佳方案：96例连续病例的结果
Br J Cancer. 1994 May;69(5):947-51. doi: 10.1038/bjc.1994.183.
3
Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients.肾上腺皮质癌的自然病史：42例患者的临床病理研究
Cancer. 1981 May 1;47(9):2153-61. doi: 10.1002/1097-0142(19810501)47:9<2153::aid-cncr2820470908>3.0.co;2-6.
4
Cis-platinum treatment of metastatic adrenal carcinoma.顺铂治疗转移性肾上腺癌。
Med J Aust. 1980 May 3;1(9):419-21. doi: 10.5694/j.1326-5377.1980.tb134997.x.
5
CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma.
Cancer Treat Rep. 1983 Apr;67(4):377-9.
6
Cisplatin for adrenal cortical carcinoma.顺铂用于肾上腺皮质癌。
Cancer Treat Rep. 1983 May;67(5):513-4.
7
Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review.
Cancer. 1984 Jan 1;53(1):26-9. doi: 10.1002/1097-0142(19840101)53:1<26::aid-cncr2820530107>3.0.co;2-i.
8
Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978).
Am J Med. 1981 Nov;71(5):855-75. doi: 10.1016/0002-9343(81)90384-3.
9
Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients.
Am J Med. 1966 Oct;41(4):581-92. doi: 10.1016/0002-9343(66)90220-8.
10
Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16).顺铂和依托泊苷（VP - 16）治疗转移性肾上腺皮质癌。
Cancer. 1986 Nov 15;58(10):2198-202. doi: 10.1002/1097-0142(19861115)58:10<2198::aid-cncr2820581006>3.0.co;2-a.
Zotero 插件